LEGN
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number is N/A due to lack of positive earnings; valuation relies entirely on forward growth projections.
- Low Price/Sales (3.26)
- Reasonable Forward P/E (15.79)
- Negative current earnings
- Price/Book of 3.35 is high for a non-profitable entity
Growth is present in revenue but not translating to the bottom line.
- High revenue growth (64%+)
- Aggressive analyst price targets
- Poor earnings track record
- Negative operating margins
Long-term price performance is overwhelmingly negative.
- 1Y Change: -41.9%
- 3Y Change: -64.1%
- Consistent earnings misses
The Piotroski score is a primary red flag for financial health.
- Low Debt/Equity
- Piotroski F-Score 1/9
- Negative ROE and ROA
Typical for biotech growth stage, but provides no yield cushion.
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LEGN and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corporation
Primary
|
-34.7% | -64.1% | -41.9% | -42.7% | -10.4% | -5.1% |
|
BLLN
BillionToOne, Inc.
Peer
|
-32.0% | -32.0% | -32.0% | -32.0% | +2.8% | +6.2% |
|
LIVN
LivaNova PLC
Peer
|
-22.5% | +45.9% | +83.9% | +23.9% | +0.8% | -1.6% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-31.3% | +1.1% | +22.8% | -12.7% | -8.3% | -7.0% |
|
BEAM
Beam Therapeutics Inc.
Peer
|
-69.2% | -29.2% | +20.1% | +45.3% | +12.2% | +1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LEGN
Legend Biotech Corporation
|
BEARISH | $3.36B | - | -29.1% | -28.8% | $18.16 | |
|
BLLN
BillionToOne, Inc.
|
BEARISH | $3.41B | 569.85 | 2.3% | 1.0% | $74.08 | Compare |
|
LIVN
LivaNova PLC
|
NEUTRAL | $3.43B | - | -19.2% | -17.5% | $62.78 | Compare |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
NEUTRAL | $3.51B | 8.96 | 39.9% | 36.5% | $20.61 | Compare |
|
BEAM
Beam Therapeutics Inc.
|
BEARISH | $3.2B | - | -47.2% | -% | $31.56 | Compare |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning LEGN from our newsroom.